Renal Outcomes with Dapagliflozin

This drug lowered the incidence of adverse outcomes in patients with chronic kidney disease.

Sodium–glucose cotransporter (SGLT)-2 inhibitors originally were developed to treat patients with type 2 diabetes, but three of them (dapagliflozin [Farxiga], canagliflozin [Invokana], and empagliflozin [Jardiance]) now have additional FDA-approved indications for improving cardiovascular (CV) or renal outcomes among specific patient subgroups. For dapagliflozin, those additional indications are restricted to heart failure–related outcomes.

Now, in an industry-sponsored, randomized trial, researchers have addressed effects of dapagliflozin on renal outcomes in adults with chronic kidney disease (glomerular filtration rate [GFR], 25–75 mL/minute/1.73 m², plus proteinuria), regardless of diabetes status. Four thousand such patients — two third…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Renal Outcomes with Dapagliflozin

Topics

Reviewing Author